Drugs / XS15
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04842513 | May 2021 → Jul 2024 | brain glioblastoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1 | NCT04688385 | Dec 2020 → Oct 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT06789198 Background | Jul 2025 → Nov 2028 expected | fibrolamellar hepatocellular carcinoma | University Hospital Tuebingen | Recruiting | No outcome recorded |
| Phase 1 | NCT05937295 Background | Sep 2023 → Sep 2026 overdue | fibrolamellar hepatocellular carcinoma | University Hospital Tuebingen | Recruiting | No outcome recorded |
| — | NCT05014607 Background | — | cancer | University Hospital Tuebingen | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XS15 | “Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant” NCT05014607 ↗ |
| Known as | Pam3Cys-GDPKHPKSF | “Pam3Cys-GDPKHPKSF (XS15) As an Immunomodulator” NCT04842513 ↗ |
| Modality | Other / unclassified | “the TLR1/2 ligand XS15” NCT04688385 ↗ |
| Route | Subcutaneous | “Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15” NCT05014607 ↗ |